VJHemOnc is committed to improving our service to you

ESH MM 2018 | A host of promising agents for myeloma: melflufen, filanesib, trametinib, selinexor

VJHemOnc is committed to improving our service to you

Enrique Ocio

Enrique Ocio, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain gives an overview of novel therapies to be used against multiple myeloma (MM), which are targeting both old an new pathways. Dr Ocio highlights new alkylating agents such as melflufen, as well as immunomodulatory agents targeting cereblon. He also highlights the cell cycle inhibitor filanesib, RAS pathway-targeting trametinib, and selinexor. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter